SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yanagawa N, Lee DBN 1992 Renal handling of calcium and phosphorus. In: CoeFL, FavusMJ (ed.) Disorders of Bone and Mineral Metabolism. Raven Press, New York, NY, USA, pp. 340.
  • 2
    Anonymous 1995 A gene (PEX) with homologies to endopeptidases is mutated in subjects with X-linked hypophosphatemic rickets. The Hyp Consortium. Nat Genet 11:130136.
  • 3
    Strewler GJ 2001 FGF23, hypophosphatemia, and rickets: Has phosphatonin been found? Proc Natl Acad Sci USA 98:59455946.
  • 4
    Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:65006505.
  • 5
    White KE, Evans WE, O'Riordan JL, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM 2000 Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345348.
  • 6
    White KE, Jonsson DG, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497500.
  • 7
    DeBeur DM, Fennegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC 2002 Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:11021110.
  • 8
    Quarles LD, Drezner MK 2001 Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: A perPHEXing problem. J Clin Endocrinol Metab 86:494496.
  • 9
    Kumar R 1997 Phosphatonin-a new phosphaturetic hormone? (Lessons from tumor-induced osteomalacia and X-linked hypophosphatasemia.) Nephrol Dial Transplant 12:1113.
  • 10
    Grieff M, Mumm S, Waeltz P, Mazzarella R, Whyte MP, Thakkar RV, Schlessinger D 1997 Expression and cloning of the human X-linked hypophosphatemia gene cDNA. Biochem Biophys Res Commun 231:635639.
  • 11
    Guo R, Liu S, Spurney RF, Quarles LD 2001 Analysis of recombinant Phex: An endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281:E837E847.
  • 12
    Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schaivi SC 2001 FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977981.
  • 13
    Weidner N, Santa Cruz D 1987 Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59:14421454.
  • 14
    Yamazaki Y, Okasaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in subjects with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:49574960.
  • 15
    Hill DJ, Flyvbjerg A, Arany E, Lauszus FF, Klebe JG 1997 Increased levels of serum fibroblast growth factor-2 in diabetic pregnant women with retinopathy. J Clin Endocrinol Metab 82:14521457.
  • 16
    Kurz C, Hefler L, Zeisler H, Schatten C, Husslein P, Tempfer C 2001 Maternal basic fibroblast growth factor serum levels are associated with pregnancy-induced hypertension. J Soc Gynecol Investig 8:2426.
  • 17
    Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P 2002 Basic fibroblast growth factor changes in response to coronary angioplasty in subjects with stable angina. Int J Cardiol 84:195199.
  • 18
    Sasaki H, Yukiue H, Kobayashi Y, Nakashima Y, Moriyama S, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y 2001 Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in subjects with thymic epithelial neoplasms. Surg Today 31:10381040.
  • 19
    Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G 1998 Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer subjects. Anticancer Res 18:11231127.
  • 20
    Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajimi T, Takeuchi Y, Futia T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in subjects with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:49574960.
  • 21
    Nakayama K 1997 Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing a wide variety to precursor proteins. Biochem J 327:625635.
  • 22
    Kumar R 2002 New insights into phosphate homeostasis: Fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens 11:547553.
  • 23
    Meyer RA Jr, Tenenhouse HS, Meyer MH, Klugerman AH 1989 The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J Bone Miner Res 4:523532.
  • 24
    Blydt-Hansen TD, Tenenhouse HS, Goodyer P 1999 PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 13:607611.
  • 25
    Posillico JT, Lobaugh B, Muhlbaier LH, Drezner MK 1985 Abnormal parathyroid function in the X-linked hypophosphatemic mouse. Calcif Tissue Int 37:418422.
  • 26
    Allen HC, Whybro A, Barker ME, Estell R, Bulumsohn A 2002 Endocrine response to escalating-dose phosphate supplementation in MEN: Is FGF-23 phosphatonin. J Bone Miner Res 17:S1;S159.
  • 27
    Yamashita T, Hasegawa H, Yamazake Y, Kawata T, Urakawa I, Shimada T, Takeuchi Y, Fujita T, Fukumoto S, Nagano N 2002 Involvement of FGF-23 in abnormal vitamin D and mineral metabolism associates with renal insufficiency. J Am Soc Nephrol 13:577A.